Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | NAE1 | Q13564 | 2/20 | 0.30 |
| ▸ | GRK5 | P34947 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.30 |
| ▸ | NEDD8 | Q15843 | 1/20 | 0.30 |
| ▸ | UBA3 | Q8TBC4 | 1/20 | 0.30 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.30 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566443 | 0.81 | KLKB1 (0.40) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL23584536 | 0.81 | ALDH1A1 (0.30) | — | |
| SCHEMBL1799305 | 0.81 | ATG7 (0.45) | — | |
| SCHEMBL23584662 | 0.80 | ABL1 (0.40) | — | |
| SCHEMBL13773407 | 0.76 | CA2 (0.43) | CA2CA1CA9 | |
| SCHEMBL23584651 | 0.75 | — | — | |
| SCHEMBL12566870 | 0.73 | ATG7 (0.43) | CA2NAE1GRK5CSNK1A1UBA6 | |
| SCHEMBL12652428 | 0.72 | BCHE (0.43) | CA2CA1CA4CA9NAE1 | |
| SCHEMBL12566880 | 0.72 | CYP1A2 (0.35) | CA2 | |
| SCHEMBL12652426 | 0.70 | ATG7 (0.46) | CA2NAE1GRK5CSNK1A1UBA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | CA2 3826/4885CA1 2434/4885CA4 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.